Radwan ِAlnajjar

Dr. Radwan ِAlnajjar

University of Benghazi, Benghazi, Banghāzī, Libya
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
DEDalia Elebeedy
Dalia Elebeedy
WEWalid F. Elkhatib
Walid F. Elkhatib
AKAhmed Kandeil
Ahmed Kandeil
AGAml Ghanem
Aml Ghanem
OKOmnia Kutkat
Omnia Kutkat
Ahmed A. Al-KarmalawyAhmed A. Al-Karmalawy
Ahmed A. Al-Karmalawy
Tanshinone IIA shows the most promising anti-SARS-CoV-2 biological activity: molecular docking, molecular dynamics, in vitro , and SAR studies.

1 December 2020 in Heliyon
Verified
Journal Article
Open access
Radwan ِAlnajjarRadwan ِAlnajjar
Radwan ِAlnajjar
Ahmed MostafaAhmed Mostafa
Ahmed Mostafa
AKAhmed Kandeil
Ahmed Kandeil
AAAhmed A. Al-Karmalawy
Ahmed A. Al-Karmalawy
Drug repurposing is the most rapid and economic way nowadays to rapidly provide effective drugs for our pandemic coronavirus disease 2019 (COVID-19). It was a great debate about ARBs whether to be stopped or continued for patients using them especially at the beginning of the COVID-19 pandemic. In this study, we carried out a virtual screening for almost all members of ARBs (nine) against COVID-19 main protease. Molecular docking as one of the important computational techniques was performed in this work. Interestingly, the tested compounds showed variable binding affinities in the order of N3 inhibitor (10, docked) > Fimasartan (8) > Candesartan (2) > Olmesartan (7) > Azilsartan (9) > Eprosartan (5) > Valsartan (3) > Losartan (1) > Irbesartan (6) > Telmisartan (4). Moreover, Fimasartan (8), Candesartan (2), and Olmesartan (7) were additionally estimated through molecular dynamic simulations monitored via computing the binding free energy using MM-GBSA. The results are promising for rapidly repurposing such drugs (especially, Fimasartan (8) and Candesartan (2)) after further preclinical and clinical studies either alone or in combination with others for the treatment of COVID-19 virus especially known to cause vasodilatation (to prevent blood coagulation) and to reduce inflammation and fibrosis (to prevent pulmonary fibrosis), with well-known safety profiles. In vitro, the virtual findings were consistent with the experimental testing of four representative ARBs. Out of the tested compounds, Olmesartan (7) showed the most promising anti-SARS-CoV-2 activity (IC50 = 1.808 μM, and CC50 = 557.6 μM) with high selectivity index (308.4) against SARS-CoV-2 in Vero E6 cells. This work may clarify and approve not only the safety of ARBs used by a large group of patients worldwide but also their possible effectiveness against the COVID-19 virus either as a prophylactic or treatment option. It intended also to give a clear spot on the structure-activity relationship (SAR) required for the future design of new drugs targeting the newly emerged SARS-CoV-2 protease by medicinal chemists.

9 March 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
AEAyman Abo Elmaaty
Ayman Abo Elmaaty
Radwan ِAlnajjarRadwan ِAlnajjar
Radwan ِAlnajjar
MHMohammed I. A. Hamed
Mohammed I. A. Hamed
Muhammad KhattabMuhammad Khattab
Muhammad Khattab
MKMohamed M. Khalifa
Mohamed M. Khalifa
Ahmed A. Al-KarmalawyAhmed A. Al-Karmalawy
Ahmed A. Al-Karmalawy
The global breakout of COVID-19 and raised death toll has prompted scientists to develop novel drugs capable of inhibiting SARS-CoV-2. Conducting studies on repurposing some FDA-approved glucocorticoids can be a promising prospective for finding a treatment for COVID-19. In addition, the use of anti-inflammatory drugs, such as glucocorticoids, is a pivotal step in the treatment of critical cases of COVID-19, as they can provoke an inflammatory cytokine storm, damaging lungs. In this study, 22 FDA-approved glucocorticoids were identified through in silico (molecular docking) studies as the potential inhibitors of COVID-19's main protease. From tested compounds, ciclesonide 11, dexamethasone 2, betamethasone 1, hydrocortisone 4, fludrocortisone 3, and triamcinolone 8 are suggested as the most potent glucocorticoids active against COVID-19's main protease. Moreover, molecular dynamics simulations followed by the calculations of the binding free energy using MM-GBSA were carried out for the aforementioned promising candidate-screened glucocorticoids. In addition, quantum chemical calculations revealed two electron-rich sites on ciclesonide where binding interactions with the main protease and cleavage of the prodrug to the active metabolite take place. Our results have ramifications for conducting preclinical and clinical studies on promising glucocorticoids to hasten the development of effective therapeutics against COVID-19. Another advantage is that some glucocorticoids can be prioritized over others for the treatment of inflammation accompanying COVID-19.

30 June 2022 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MHMohamed elmettwaly Hammouda
Mohamed elmettwaly Hammouda
AMAyman Mohamed
Ayman Mohamed
MNMohamed S. Nafie
Mohamed S. Nafie
MAMarwa Abdelmotaal
Marwa Abdelmotaal
NMNoha S. Mohamed
Noha S. Mohamed
Ahmed A. Al-KarmalawyAhmed A. Al-Karmalawy
Ahmed A. Al-Karmalawy

8 February 2022 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
RERana M. El-Masry
Rana M. El-Masry
Ahmed A. Al-KarmalawyAhmed A. Al-Karmalawy
Ahmed A. Al-Karmalawy
Radwan ِAlnajjarRadwan ِAlnajjar
Radwan ِAlnajjar
SMSara H. Mahmoud
Sara H. Mahmoud
Ahmed MostafaAhmed Mostafa
Ahmed Mostafa
ATAzza Taher
Azza Taher
The pharmacophoric features of the novel series of 1,3,4-oxadiazole–oxoindole conjugates (IVa–g) as potential anti-SARS-CoV-2 agents based on the reported Mproinhibitor (Ia) are presented.

1 February 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
DEDalia Elebeedy
Dalia Elebeedy
IBIngy Badawy
Ingy Badawy
AMAyman Mohamed
Ayman Mohamed
MSMoustafa M. Saleh
Moustafa M. Saleh
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
Ahmed A. Al-KarmalawyAhmed A. Al-Karmalawy
Ahmed A. Al-Karmalawy